肾移植术后合并肾功能不全患者感染新型冠状病毒后继发肺孢子菌肺炎的药物治疗实践一例  

A case of drug therapy practice of pneumocystis jirovecii pneumonia secondary to COVID-19 in patient with renal insufficiency after renal transplantation

作　　者：王小营 李忠东 WANG Xiao-ying;LI Zhong-dong(Department of Pharmacy,Beijing Electric Power Hospital of State Grid Co.of China,Capital Medical University Electric Teaching Hospital,Beijing 100073,China)

机构地区：[1]国家电网公司北京电力医院首都医科大学电力教学医院药剂科,北京100073

出　　处：《临床药物治疗杂志》2024年第3期89-92,共4页Clinical Medication Journal

摘　　要：本文报道1例肾移植术后合并肾功能不全患者感染新型冠状病毒后继发肺孢子菌肺炎(PCP)的诊疗经过。临床药师会诊,根据患者的病理生理特点、实验室检查结果,协助医师制订复方磺胺甲噁唑注射液联合卡泊芬净静脉滴注的治疗方案,患者病情好转后调整为复方磺胺甲噁唑片口服联合卡泊芬净静脉滴注。在整个治疗过程中,未发生严重不良反应,最终患者病情控制并顺利出院。This report is the diagnostic and therapeutic process of a hemodialysis patient after renal transplantation who developed pneumocystis jirovecii pneumonia(PCP)following COVID-19.According to the patient's pathophysiological characteristics and laboratory examination results,clinical pharmacists carried out consultations,assisting in formulating the initial treatment plan of sulfamethoxazole-trimethoprim for injection combined with caspofungin,and carried out pharmaceutical care.After the patient's condition improved,clinical pharmacists suggested adjusting the injection form of sulfamethoxazoletrimethoprim to oral form.No serious adverse reactions occurred during the entire PCP treatment process,and finally,the patient was successfully discharged.

关 键 词：肺孢子菌肺炎 肾移植 磺胺甲噁唑 甲氧苄啶 卡泊芬净 

分 类 号：R978.5[医药卫生—药品]